OsteoDex for multiple myeloma in previously treated patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new drug called OsteoDex (ODX) for people with multiple myeloma whose cancer has continued to worsen after trying 1 to 5 earlier treatments. The goal is to see if OsteoDex can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or gotten worse after 1 to 5 prior treatments.
- You have had at least one of these types of drugs: a proteasome inhibitor (like bortezomib), an immunomodulator (like lenalidomide), and a CD38 antibody (like daratumumab).
- Your cancer is measurable with a simple blood or urine test.
- You are 18 years or older and in generally good enough health to be up and about (ECOG 0-2).
- Your lab work shows adequate kidney, liver, and blood cell counts.
- If you are able to have children, you must use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
This study is testing new drugs for people recently diagnosed with multiple myeloma, a blood cancer. It aims to see if the new treatment is safe and effective, and it may offer an additional treatment option.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.